# TAS-102 in Treating Advanced Biliary Tract Cancers

> **NCT03278106** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 28 (actual)

## Conditions studied

- Cholangiocarcinoma
- Stage III Gallbladder Cancer AJCC v7
- Stage IIIA Gallbladder Cancer AJCC v7
- Stage IIIB Gallbladder Cancer AJCC v7
- Stage IV Gallbladder Cancer AJCC v7
- Stage IVA Gallbladder Cancer AJCC v7
- Stage IVB Gallbladder Cancer AJCC v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102

## Key facts

- **NCT ID:** NCT03278106
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-20
- **Primary completion:** 2018-11-30
- **Final completion:** 2021-09-16
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03278106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03278106, "TAS-102 in Treating Advanced Biliary Tract Cancers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03278106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*